Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: To evaluate the impact of isoniazid (INH) treatment for latent tuberculosis infection (LTBI) on the development of liver function test (LFT) abnormality and the persistence of tumor necrosis factor (TNF) inhibitors in rheumatoid arthritis (RA) patients. Methods: We retrospectively enrolled patients with RA who were treated with TNF inhibitors at a university hospital between December 2000 and November 2011. After dividing the patients into two groups based on the occurrence of LFT abnormality during follow-up, we compared demographic and clinical features between the two groups. A multivariable logistic regression analysis was performed to identify the impact of INH treatment on LFT abnormality. The impact of INH treatment on the persistence of TNF inhibitors was also evaluated with the log-rank test and the Cox-proportional hazards model. Results: A total of 312 RA patients including 96 patients (30.9%) who took INH for LTBI were included in this analysis. Thirty-nine patients (12.5%) experienced LFT abnormalities while using TNF inhibitors. The use of INH was associated with LFT abnormalities (odds ratio, 3.01; 95% confidence interval [CI], 1.39 to 6.48) after adjusting for covariates, including methotrexate use. However, the persistence of TNF inhibitors over 5 years did not differ between patients receiving or not receiving INH treatment (49.4 vs. 54.6%, p = 0.79). INH treatment was not a risk factor for discontinuation of TNF inhibitors (hazard ratio, 1.01; 95% CI, 0.66 to 1.57). Conclusion: INH treatment for LTBI in RA patients who started TNF inhibitors is associated with the occurrence of LFT abnormality; however, it does not lead to discontinuation of TNF inhibitors.
Abstract
Background/Aims: To evaluate the impact of isoniazid (INH) treatment for latent tuberculosis infection (LTBI) on the development of liver function test (LFT) abnormality and the persistence of tumor necrosis factor (TNF) inhibitors in rheumatoid arthritis (RA) patients. Methods: We retrospectively enrolled patients with RA who were treated with TNF inhibitors at a university hospital between December 2000 and November 2011. After dividing the patients into two groups based on the occurrence of LFT abnormality during follow-up, we compared demographic and clinical features between the two groups. A multivariable logistic regression analysis was performed to identify the impact of INH treatment on LFT abnormality. The impact of INH treatment on the persistence of TNF inhibitors was also evaluated with the log-rank test and the Cox-proportional hazards model. Results: A total of 312 RA patients including 96 patients (30.9%) who took INH for LTBI were included in this analysis. Thirty-nine patients (12.5%) experienced LFT abnormalities while using TNF inhibitors. The use of INH was associated with LFT abnormalities (odds ratio, 3.01; 95% confidence interval [CI], 1.39 to 6.48) after adjusting for covariates, including methotrexate use. However, the persistence of TNF inhibitors over 5 years did not differ between patients receiving or not receiving INH treatment (49.4 vs. 54.6%, p = 0.79). INH treatment was not a risk factor for discontinuation of TNF inhibitors (hazard ratio, 1.01; 95% CI, 0.66 to 1.57). Conclusion: INH treatment for LTBI in RA patients who started TNF inhibitors is associated with the occurrence of LFT abnormality; however, it does not lead to discontinuation of TNF inhibitors.
참고문헌 (17)
- "Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement", Am J Respir Crit Care Med, 161(4), pp.S221~S247 (2000)[DOI]
- Joint Tuberculosis Committee of the British Thoracic Society, "Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998", Thorax, 53, pp.536~548 (1998)[DOI]
- Centers for Disease Control and Prevention (CDC), "Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection", MMWR Morb Mortal Wkly Rep, 60, pp.1650~1653 (2011)
- Nolan CM, "Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic", JAMA, 281, pp.1014~1018 (1999)[DOI]
- Kremer JM, "Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis", J Rheumatol, 23, pp.459~461 (1996)
- Siva C, "Leflunomide use during the first 33 months after food and drug administration approval: experience with a national cohort of 3,325 patients", Arthritis Rheum, 49, pp.745~751 (2003)[DOI]
- Kalden JR, "The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study", Arthritis Rheum, 48, pp.1513~1520 (2003)[DOI]
- Vanhoof J, "High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors", Ann Rheum Dis, 62, pp.1241~1242 (2003)[DOI]
- Mor A, "Methotrexate combined with isoniazid treatment for latent tuberculosis is well tolerated in patients with rheumatoid arthritis: experience from an urban arthritis clinic", Ann Rheum Dis, 67, pp.462~465 (2008)
- 조수경, "한국인 류마티스관절염 환자에서 항 TNF 제제의 지속성에 관한 연구", 대한류마티스학회지, 18(3), pp.161~167 (2011), 대한류마티스학회
- Sokolove J, "Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis", Ann Rheum Dis, 69, pp.1612~1617 (2010)[DOI]
- Kim JH, "Factors influencing discrepancies between the QuantiFERON-TB gold in tube test and the tuberculin skin test in Korean patients with rheumatic diseases", Semin Arthritis Rheum, 42, pp.424~432 (2013)[DOI]
- Marques CD, "Evaluation of an interferon gamma assay in the diagnosis of latent tuberculosis infection in patients with rheumatoid arthritis", Rheumatol Int, 30, pp.57~62 (2009)[DOI]
- Mariette X, "Influence of replacing tuberculin skin test with ex vivo interferon <TEX>$\gamma$<", TEX> release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy, 2012, pp.71, 1783~1790
- Martin J, "Comparison of interferon {gamma} release assays and conventional screening tests before tumour necrosis factor {alpha} blockade in patients with inflammatory arthritis", Ann Rheum Dis, 69, pp.181~185 (2010)[DOI]
- Scrivo R, "Serial interferon-<TEX>$\gamma$<", TEX> release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents, 2012, pp.31, 1567~1575
- "Guidance for industry drug-induced liver injury: premarketing clinical evaluation" (2009)[URL]